Fasting Study of Oxybutynin Chloride Extended-Release Tablets 5 mg and Ditropan XL® Tablets 5 mg
Status:
Completed
Trial end date:
2003-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the single-dose relative bioavailability of
Mylan's oxybutynin chloride Extended-release tablets to ALZA's Ditropan XL® tablets following
a single, oral 20 mg (4 x 5 mg) dose under fasting conditions.